We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Perrigo's Stock Up, Starboard's CEO Calls it a Key Pick
Read MoreHide Full Article
Perrigo Company plc’s (PRGO - Free Report) shares increased almost 5% after Jeff Smith, CEO of Starboard Value, a New York-based investment consulting company, declared that the company was a top investment option at the Delivering Alpha event hosted by CNBC.
Notably, Perrigo is one of the world’s largest manufacturers of over-the-counter (OTC) healthcare products and supplier of infant formulas for the store brand market. It is a leading provider of branded OTC products in the EU and the United States. The company also produces generic standard topical products.
However, Perrigo’s shares have underperformed the industry so far this year. The stock has gained 7% compared with the broader industry’s 21.7% increase.
During the conference, Jeff stated that Perrigo is undervalued at present due to pricing pressure, particularly in generics segment and because of changing dynamics in the United States. He continued to say that the company holds huge potential as a much larger business on the whole when compared with any single brand.
He further added that though many retailers are facing online challenges from e-commerce giants like Amazon (AMZN - Free Report) , Perrigo can utilize it as a prime distribution outlet for generic drugs and other over-the-counter (OTC) products.
At the conference, Jeff Smith also cited Altaba Inc. , a New York based investment company as another good option for investors to put money in.
We remind investors that Jeff Smith has placed a total of five members on the company’s board including two new ones who came late in 2016.
ACADIA’s loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Perrigo's Stock Up, Starboard's CEO Calls it a Key Pick
Perrigo Company plc’s (PRGO - Free Report) shares increased almost 5% after Jeff Smith, CEO of Starboard Value, a New York-based investment consulting company, declared that the company was a top investment option at the Delivering Alpha event hosted by CNBC.
Notably, Perrigo is one of the world’s largest manufacturers of over-the-counter (OTC) healthcare products and supplier of infant formulas for the store brand market. It is a leading provider of branded OTC products in the EU and the United States. The company also produces generic standard topical products.
However, Perrigo’s shares have underperformed the industry so far this year. The stock has gained 7% compared with the broader industry’s 21.7% increase.
During the conference, Jeff stated that Perrigo is undervalued at present due to pricing pressure, particularly in generics segment and because of changing dynamics in the United States. He continued to say that the company holds huge potential as a much larger business on the whole when compared with any single brand.
He further added that though many retailers are facing online challenges from e-commerce giants like Amazon (AMZN - Free Report) , Perrigo can utilize it as a prime distribution outlet for generic drugs and other over-the-counter (OTC) products.
At the conference, Jeff Smith also cited Altaba Inc. , a New York based investment company as another good option for investors to put money in.
We remind investors that Jeff Smith has placed a total of five members on the company’s board including two new ones who came late in 2016.
Perrigo Company Price
Perrigo Company Price | Perrigo Company Quote
Zacks Rank & Stock to Consider
Perrigo currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the pharma sector is ACADIA Pharmaceuticals Inc. (ACAD - Free Report) holding a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ACADIA’s loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>